This experiment addresses the #2 ranked PD knowledge gap: "Which early-PD subgroups truly benefit from GLP-1 pathway therapies?" (32 points). The lixisenatide trial showed promise but effect heterogeneity suggests subgroups respond differently — identifying responders could unlock precision medicine for neuroprotection.
Key Question
What baseline biological features predict response to GLP-1 receptor agonist therapy in early Parkinson's disease?
Study Design
...
GLP-1 Agonist Responder Prediction Study
Overview
Mermaid diagram (expand to render)
This experiment addresses the #2 ranked PD knowledge gap: "Which early-PD subgroups truly benefit from GLP-1 pathway therapies?" (32 points). The lixisenatide trial showed promise but effect heterogeneity suggests subgroups respond differently — identifying responders could unlock precision medicine for neuroprotection.
Key Question
What baseline biological features predict response to GLP-1 receptor agonist therapy in early Parkinson's disease?
Study Design
Rationale
The lixisenatide Phase 2 trial showed slower motor progression over 12 months (MDS-UPDRS difference of ~3 points), but the effect was not universal. Understanding who responds enables:
Patient selection for next-phase trials
Mechanistic understanding of GLP-1 neuroprotection
Development of combination therapies for non-responders
Prospective Biomarker-Guided Study
Recruit 400 early-PD patients (Hoehn-Yahr 1-2, disease duration < 2 years) and profile at baseline:
Combination: Design rational combinations for non-responders
Feasibility Assessment
| Factor | Assessment | |--------|------------| | Technical Feasibility | High — all assays established | | Recruitment Feasibility | High — early PD population accessible | | Cost Estimate | $15-20M over 3 years | | Timeline | 36 months to primary readout | | Cross-Disease Value | High — applies to AD, ALS, other neurodegeneration |
[Pagano et al., Trial of Lixisenatide in Early Parkinson's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38598572)
[Stott et al., Are GLP-1R agonists useful in treating PD? (2025)](https://pubmed.ncbi.nlm.nih.gov/39864104)
[Zhang et al., Antidiabetic drugs in PD: efficacy and safety meta-analysis (2025)](https://pubmed.ncbi.nlm.nih.gov/40762930)
[GLP-1 receptor expression in human brain (2024)](https://pubmed.ncbi.nlm.nih.gov/)
Pathway Diagram
The following diagram shows the key molecular relationships involving GLP-1 Agonist Responder Prediction Study — Precision Medicine for Neuroprotection in PD discovered through SciDEX knowledge graph analysis: